Literature DB >> 7841043

Interaction of tamoxifen with the multidrug resistance P-glycoprotein.

R Callaghan1, C F Higgins.   

Abstract

Tamoxifen is an anti-oestrogen which is currently being assessed as a prophylactic for women at high risk of breast cancer. Taxoxifen has also been shown to reverse multidrug resistance in P-glycoprotein (P-gp)-expressing cells, although the mechanism of action is unknown. In this study we demonstrate that tamoxifen interacts directly with P-gp. Plasma membranes from P-gp-expressing cells bound [3H]tamoxifen in a specific and saturable fashion. A 180 kDa membrane protein in these membranes, labelled by the affinity analogue tamoxifen aziridine and azidopine, was shown to be P-gp. Tamoxifen reduced the binding of vinblastine and azidopine to P-gp, and tamoxifen increased [3H]vinblastine accumulation in P-gp-expressing cells to levels approaching those in non-P-gp-expressing cells. However, the cellular accumulation of [3H]tamoxifen itself was not influenced by the presence of P-gp. Thus, tamoxifen appears to reverse multidrug resistance by binding to P-gp and inhibiting the transport of cytotoxic drugs, but does not itself appear to be transported by the protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7841043      PMCID: PMC2033580          DOI: 10.1038/bjc.1995.59

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.

Authors:  K Yusa; T Tsuruo
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

2.  ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.

Authors:  M Horio; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens.

Authors:  D Kessel
Journal:  Biochem Pharmacol       Date:  1986-08-15       Impact factor: 5.858

4.  Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers.

Authors:  A R Safa; C J Glover; J L Sewell; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

5.  Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine.

Authors:  E P Bruggemann; U A Germann; M M Gottesman; I Pastan
Journal:  J Biol Chem       Date:  1989-09-15       Impact factor: 5.157

6.  Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies.

Authors:  A Yoshimura; Y Kuwazuru; T Sumizawa; M Ichikawa; S Ikeda; T Uda; S Akiyama
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

7.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.

Authors:  C P Yang; S G DePinho; L M Greenberger; R J Arceci; S B Horwitz
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

8.  Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation.

Authors:  D F Cano-Gauci; J R Riordan
Journal:  Biochem Pharmacol       Date:  1987-07-01       Impact factor: 5.858

9.  Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells.

Authors:  M M Cornwell; M M Gottesman; I H Pastan
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

10.  Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.

Authors:  M W DeGregorio; J M Ford; C C Benz; V J Wiebe
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

View more
  24 in total

1.  MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.

Authors:  T A Bogush; E A Dudko; E A Bogush; M V Tikhomirov; V Yu Kirsanov; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2010 Jan-Feb       Impact factor: 0.788

2.  A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.

Authors:  E A Bogush; A B Ravcheeva; T A Bogush; T N Zabotina; Z G Kadagidze; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2007 Mar-Apr       Impact factor: 0.788

3.  Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates To Overcome Cancer Resistance.

Authors:  Gaia Fumagalli; Giulia Giorgi; Máté Vágvölgyi; Eleonora Colombo; Michael S Christodoulou; Veronica Collico; Davide Prosperi; Franco Dosio; Attila Hunyadi; Monica Montopoli; Mariafrancesca Hyeraci; Alessandra Silvani; Giordano Lesma; Lisa Dalla Via; Daniele Passarella
Journal:  ACS Med Chem Lett       Date:  2018-04-17       Impact factor: 4.345

Review 4.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

Review 5.  Challenges and Potential for Ovarian Preservation with SERMs.

Authors:  Alison Y Ting; Brian K Petroff
Journal:  Biol Reprod       Date:  2015-03-25       Impact factor: 4.285

6.  Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Authors:  Samy A F Morad; Traci S Davis; Matthew R MacDougall; Su-Fern Tan; David J Feith; Dhimant H Desai; Shantu G Amin; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2017-02-09       Impact factor: 5.858

7.  Tamoxifen inhibits acidification in cells independent of the estrogen receptor.

Authors:  N Altan; Y Chen; M Schindler; S M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

8.  In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus.

Authors:  María Celeste Nicolao; María Celina Elissondo; Guillermo M Denegri; Alejandra B Goya; Andrea C Cumino
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

9.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.

Authors:  Samy A F Morad; Jonathan C Levin; Sriram S Shanmugavelandy; Mark Kester; Gemma Fabrias; Carmen Bedia; Myles C Cabot
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.